Inventor :

Dong

Serial No. Filed

10/629,261 07/28/2003

Page

: 2

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS (Currently amended claims showing deletions by underlining or double underlining)

1 (currently amended): A compound of formula (I),  $(R^2R^3)-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}-A^{18}-A^{19}-A^{20}-A^{21}-A^{22}-A^{23}-A^{24}-A^{25}-A^{26}-A^{27}-A^{28}-A^{29}-A^{30}-A^{31}-A^{32}-A^{33}-A^{34}-A^{35}-A^{36}-A^{37}-A^{38}-A^{39}-R^1 (SEQ ID NO:412),$ 

**(I)** 

wherein

A<sup>7</sup> is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A<sup>8</sup> is Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;

A<sup>9</sup> is Glu, N-Me-Glu, N-Me-Asp or Asp;

 $A^{10}$  is Gly, Acc,  $\beta$ -Ala or Aib;

A<sup>11</sup> is Thr or Ser;

A<sup>12</sup> is Phe, Acc, Aic, Aib, 3-Pal, 4- Pal, β-Nal, Cha, Trp or X<sup>1</sup>-Phe;

A<sup>13</sup> is Thr or Ser;

A<sup>14</sup> is Ser or Aib;

A<sup>15</sup> is Asp or Glu;

A<sup>16</sup> is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;

A<sup>17</sup> is Ser or Thr;

A<sup>18</sup> is Ser or Thr;

A<sup>19</sup> is Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal or X<sup>1</sup>-Phe;

A<sup>20</sup> is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X<sup>1</sup>-Phe;

A<sup>21</sup> is Glu or Asp;

 $A^{22}$  is Gly, Acc,  $\beta$ -Ala, Glu or Aib;

A<sup>23</sup> is Gln, Asp, Asn or Glu;

A<sup>24</sup> is Ala, Aib, Val, Abu, Tle or Acc;

 $A^{25}$  is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O) or NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);

 $A^{26}$  is Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O) or NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);  $A^{27}$  is Glu Asp, Leu, Aib or Lys;

Dong 10/629,261 07/28/2003

Page

Filed

3

A<sup>28</sup> is Phe, Pal, β- Nal, X<sup>1</sup>-Phe, Aic, Acc, Aib, Cha or Trp;

A<sup>29</sup> is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;

A<sup>30</sup> is Ala, Aib or Acc;

A<sup>31</sup> is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;

A<sup>32</sup> is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X<sup>1</sup>-Phe or Ala;

A<sup>33</sup> is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X<sup>1</sup>-Phe;

 $A^{34}$  is Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O) or NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O);

A<sup>35</sup> is Gly, β-Ala, D-Ala, Gaba, Ava, NH-(CH<sub>2</sub>)<sub>m</sub>-C(O), Aib, Acc or a D-amino acid;

 $A^{36}$  is L-or D-Arg, D-or L-Lys, D-or L-hArg, D-or L-Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O), NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O) or deleted;

 $A^{37}$  is Gly,  $\beta$ -Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, NH-(CH<sub>2</sub>)<sub>m</sub>-C(O), HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O), a D-amino acid, or deleted;

A<sup>38</sup> is D-or L-Lys, D-or L-Arg, D-or L-hArg, D-or L-Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O), NH-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O), Ava, Ado, Aec or deleted;

A<sup>39</sup> is D-or L-Lys, D-or L-Arg, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>-R<sup>11</sup>))-C(O), Ava, Ado, or Aec;

 $X^1$  for each occurrence is independently selected from the group consisting of ( $C_1$ - $C_6$ )alkyl, OH and halo;

 $R^1$  is OH, NH<sub>2</sub>, (C<sub>1</sub>-C<sub>30</sub>) alkoxy, or NH-X<sup>2</sup>-CH<sub>2</sub>-Z<sup>0</sup>, wherein X<sup>2</sup> is a (C<sub>1</sub>-C<sub>12</sub>) hydrocarbon moiety, and Z<sup>0</sup> is H, OH, CO<sub>2</sub>H or CONH<sub>2</sub>;

$$X^4$$
 N  $-(CH_2)_f$  -CH<sub>3</sub>

 $X^3$  is

or -C(O)-NHR<sup>12</sup>, wherein  $X^4$  is, independently for each occurrence, -C(O)-, -NH-C(O)- or -CH<sub>2</sub>-, and wherein f is , independently for each occurrence, an integer from 1 to 29 inclusive; each of  $R^2$  and  $R^3$  is, independently for each occurrence, H[[,]]

e is, independently for each occurrence, an integer from 1 to 4 inclusive;

Page:

m is, independently for each occurrence, an integer from 5 to 24 inclusive; n is, independently for each occurrence, an integer from 1 to 5, inclusive; each of  $R^{10}$  and  $R^{11}$  is, independently for each occurrence, H,  $(C_1-C_{30})$  alkyl,  $(C_1-C_{30})$  acyl,  $(C_1-C_{30})$  alkylsulfonyl,  $-C((NH)(NH_2))$  or

; and

 $R^{12}$  and  $R^{13}$  each is, independently for each occurrence,  $(C_1-C_{30})$  alkyl; provided that:

- (i) when  $A^7$  is Ura, Paa or Pta, then  $R^2$  and  $R^3$  are deleted;
- (ii) when  $R^{10}$  is  $(C_1-C_{30})$  acyl,  $(C_1-C_{30})$  alkylsulfonyl,  $-C((NH)(NH_2))$  or

-C(O)-CH
$$_2$$
—N—(CH $_2$ ) $_f$ -CH $_3$ , then R $^{11}$  is H or (C $_1$ -C $_{30}$ )alkyl;

- (iii) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-36, -37 or -38)NH<sub>2</sub> or hGLP-1(7-36, -37 or -38)OH;
- (iv) a compound of formula (I) is not an analogue of hGLP-1(7-36, -37 or -38)NH<sub>2</sub> or hGLP-1(7-36, -37 or -38)OH wherein a single position has been substituted by Ala;
- (v) a compound of formula (I) is not  $(Arg^{26,34}, Lys^{38})hGLP-1(7-38)-E$ ,  $(Lys^{26}(N_MN^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$ ,  $(Lys^{34}(N_MN^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$ ,  $(Lys^{26,34}-bis(N_MN^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$ ,  $(Arg^{26,34}(N_MN^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$ ,  $(Arg^{26,34}, Lys^{36}(N_MN^{\epsilon}-alkanoyl))hGLP-1(7-36, -37 \text{ or } -38)-E$  or  $(Arg^{26,34}, Lys^{38}(N_MN^{\epsilon}-alkanoyl))hGLP-1(7-38)-E$ , wherein E is -OH or -NH<sub>2</sub>;
- (vi) a compound of formula (I) is not  $Z^{1}(Z^{1})$ -hGLP-1(7-36, -37 or -38)-OH,  $Z^{1}(Z^{1})$ -hGLP-1(7-36, -37 or -38)-NH<sub>2</sub>, wherein  $Z^{1}$  is selected from the group consisting of:

(c) at least one of (Aib<sup>8</sup>), (D-Ala<sup>8</sup>) and (Asp<sup>9</sup>); and

Inventor Serial No.

Dong 10/629,261

Filed

07/28/2003

Page

4

(d) (Tyr<sup>7</sup>), (N acyl His<sup>7</sup>), (N alkyl His<sup>7</sup>), (N acyl D His<sup>7</sup>) or (N alkyl D His<sup>7</sup>);

- (vii) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (vi)(a) to (vi)(d); and
- (viii) a compound of formula (I) is not (N-Me-Ala<sup>8</sup>)hGLP-1(8-36 or -37), (Glu<sup>15</sup>)hGLP-1(7-36 or -37), (Asp<sup>21</sup>)hGLP-1(7-36 or -37)-or, (Phe<sup>31</sup>)hGLP-1(7-36 or -37), or (Aib<sup>8, 35</sup>)hGLP-1(7-36)NH<sub>2</sub>;

or a pharmaceutically acceptable salt thereof.

- 2 (original): A compound according to claim 1, wherein A<sup>11</sup> is Thr; A<sup>13</sup> is Thr; A<sup>15</sup> is Asp; A<sup>17</sup> is Ser; A<sup>18</sup> is Ser; A<sup>21</sup> is Glu; A<sup>23</sup> is Gln or Glu; A<sup>27</sup> is Glu; A<sup>31</sup> is Trp; or a pharmaceutically acceptable salt thereof.
- 3 (original): A compound according to claim 2, wherein A<sup>9</sup> is Glu, N-Me-Glu or N-Me-Asp; A<sup>12</sup> is Phe, Acc or Aic; A<sup>16</sup> is Val, Acc or Aib; A<sup>19</sup> is Tyr; A<sup>20</sup> is Leu, Acc or Cha; A<sup>24</sup> is Ala, Aib or Acc; A<sup>25</sup> is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH((CH<sub>2</sub>)<sub>n</sub>-N(R<sup>10</sup>R<sup>11</sup>))-C(O) or HN-CH((CH<sub>2</sub>)<sub>e</sub>-X<sup>3</sup>)-C(O); A<sup>28</sup> is Phe; A<sup>29</sup> is Ile or Acc; A<sup>30</sup> is Ala or Aib; A<sup>32</sup> is Leu, Acc or Cha; and A<sup>33</sup> is Val or Acc; or a pharmaceutically acceptable salt thereof.
- 4 (original): A compound according to claim 3, wherein  $A^8$  is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;  $A^{10}$  is Gly;  $A^{12}$  is Phe, A6c or A5c;  $A^{16}$  is Val, A6c or A5c;  $A^{20}$  is Leu, A6c, A5c or Cha;  $A^{22}$  is Gly,  $\frac{9}{2}$ -Ala or Aib;  $A^{24}$  is Ala or Aib;  $A^{29}$  is Ile, A6c or A5c;  $A^{32}$  is Leu, A6c, A5c or Cha;  $A^{33}$  is Val, A6c or A5c;  $A^{35}$  is Aib,  $\beta$ -Ala, Ado, A6c, A5c or Gly; and  $A^{37}$  is Gly, Aib,  $\beta$ -Ala, Ado, D-Ala or deleted; or a pharmaceutically acceptable salt thereof.
- 5 (original): A compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein  $X^4$  for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; and  $R^1$  is OH or NH<sub>2</sub>.
  - 6 (withdrawn) A compound according to claim 5 or a pharmaceutically

Inventor

Dong

Serial No. Filed

10/629,261 07/28/2003

Page

6

acceptable salt thereof, wherein  $R^2$  is H and  $R^3$  is  $(C_1-C_{30})$ alkyl,  $(C_2-C_{30})$ alkenyl,  $(C_1-C_{30})$ alkylsulfonyl,

7 (original): A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein  $R^{10}$  is  $(C_1-C_{30})$ acyl,  $(C_1-C_{30})$ alkylsulfonyl or

-C(O)-CH<sub>2</sub>—N—(CH<sub>2</sub>)<sub>f</sub>-CH<sub>3</sub>, and 
$$\mathbb{R}^{11}$$
 is H.

8 (original): A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein  $R^{10}$  is  $(C_4-C_{20})$ acyl,  $(C_4-C_{20})$ alkylsulfonyl or

9 (currently amended): A compound according to claim 1 wherein said compound is:

(Aib<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub>(SEQ ID NO:5),

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>( $N_M N^{\epsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub>(SEQ ID NO:6),

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sub>M</sub>N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub>(SEQ ID NO:7),

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>( $N_M N^{\epsilon}$ -tetradecanoyl))hGLP-1(7-38)NH<sub>2</sub>(SEQ ID NO:8),

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>( $N_M N^{\epsilon}$ -decanoyl))hGLP-1(7-36)NH<sub>2</sub>(SEQ ID NO:9),

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sub>M</sub>N<sup>ε</sup>-dodecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:10),

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>( $N_M N^\epsilon$ -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:11),

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-tetradecyl-piperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:12),

Inventor Serial No.

Dong

Filed

10/629,261 07/28/2003

Page

7

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-tetradecylamino))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:13), (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>( $N_M N^\epsilon$ -tetradecanoyl),  $N_B A L^{37}$ )hGLP-1(7-37)-OH (SEQ ID NO:14) or (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>( $N_M N^\epsilon$ -tetradecanoyl))hGLP-1(7-36)-OH (SEQ ID NO:15), or a pharmaceutically acceptable salt thereof.

10 (original): A compound according to claim 9 wherein said compound is  $(Aib^8, \beta-Ala^{35})hGLP-1(7-36)NH_2$  (SEQ ID NO:5),  $(Aib^{8,35}, Arg^{26}, Lys^{34}(N_M\underline{N}^\epsilon-tetradecanoyl))hGLP-1(7-36)NH_2$  (SEQ ID NO:7),  $(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N_M\underline{N}^\epsilon-tetradecanoyl))hGLP-1(7-38)NH_2$  (SEQ ID NO:8),  $(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_M\underline{N}^\epsilon-tetradecanoyl))hGLP-1(7-36)NH_2$  (SEQ ID NO:9), or  $(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_M\underline{N}^\epsilon-tetradecanoyl), \beta-Ala^{37})hGLP-1(7-37)-OH$  (SEQ ID NO:14), or a pharmaceutically acceptable salt thereof.

- 11 (original): A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
- 12 (withdrawn): A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 13 (withdrawn): A method for treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease, in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

14 (withdrawn):

A method according to claim 13 wherein said disease is

Page :

Type I diabetes or Type II diabetes.

15 (currently amended): A compound according to claim 1 wherein said compound

```
is:
(Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:71);
(\beta-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:72);
(Aib<sup>8</sup>, A6c<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:77);
(Aib<sup>8</sup>, A5c<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:78);
(Aib<sup>8</sup>, D-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:79);
(Aib<sup>8,35</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:16);
(Aib<sup>8,35</sup>, A5c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:80);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:17);
(Aib 8,24,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:18);
(Aib 8,30,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:81);
(Aib 8,25,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:82);
(Aib<sup>8,35</sup>, A6c<sup>16,20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:83);
(Aib<sup>8,35</sup>, A6c<sup>16,29,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:84);
(Aib<sup>8,35</sup>, A6c<sup>20,32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:85);
(Aib<sup>8,35</sup>, A6c<sup>20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:86);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:87);
(Aib<sup>8,24,35</sup>, A6c<sup>20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:88);
(Aib^{8,35}, A6c^{29,32})hGLP-1(7-36)NH_2 (SEQ ID NO:89);
(Aib^{8,24,35}, A6c^{29,32})hGLP-1(7-36)NH_2 (SEQ ID NO:90);
(Aib<sup>8,35</sup>, A6c<sup>12</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:91);
(Aib<sup>8,35</sup>, Cha<sup>20</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:92);
(Aib<sup>8,35</sup>, A6c<sup>33</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:93);
(Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH_2 (SEQ ID NO:85);
(Aib<sup>8</sup>, A6c<sup>16,20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:94);
(Aib<sup>8,35</sup>, \beta-Ala<sup>22</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:95);
(Aib<sup>8,22,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:96);
```

Page:

```
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:19);
(Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:97);
(Aib<sup>8,24,25,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:98);
(Aib<sup>8,24,25,35</sup>, A6c<sup>16,20,32</sup>, Glu<sup>23</sup>,)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:99);
(Aib<sup>8</sup>, A6c<sup>32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:100);
(Aib<sup>8</sup>, A5c<sup>32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:101);
(Aib<sup>8</sup>, Glu<sup>23</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:20);
(Aib^{8,24}, \beta-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:102);
(Aib<sup>8,30</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:103);
(Aib<sup>8,25</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:104);
(Aib<sup>8</sup>, A6c<sup>16,20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:94);
(Aib<sup>8</sup>, A6c<sup>16,29,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:105);
(Aib<sup>8</sup>, A6c<sup>20,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:106);
(Aib<sup>8</sup>, A6c<sup>20</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:107);
(Aib<sup>8</sup>, Lys<sup>25</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:108);
(Aib^{8,24}, A6c^{20}, β-Ala^{35})hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:109);
(Aib<sup>8</sup>, A6c<sup>29,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:110);
(Aib<sup>8,24</sup>, A6c<sup>29,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:111);
(Aib<sup>8</sup>, A6c<sup>12</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:112);
(Aib<sup>8</sup>, Cha<sup>20</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:113);
(Aib<sup>8</sup>, A6c<sup>33</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:114);
(Aib<sup>8</sup>, A6c<sup>20,32</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:106);
(Aib<sup>8</sup>, \beta-Ala<sup>22,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:115);
(Aib<sup>8,22</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:116);
(Aib<sup>8</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:117);
(Aib^{8,24}, Glu^{23}, A6c^{32}, \beta-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:118);
(Aib<sup>8,24</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N_M N^{\epsilon}-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:119);
(Aib^{8,24,25}, Glu^{23}, A6c^{32}, \beta-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:120);
```

```
07/28/2003
Filed
                                       10
Page
(Aib<sup>8,24,25</sup>, A6c<sup>16,20,32</sup>, Glu<sup>23</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:121);
(Aib<sup>8,35</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:122);
(Aib<sup>8,35</sup>, D-Lys<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:123);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:124);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Lys<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:125);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>,)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:21);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:126);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:127);
(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:128);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-36)OH (SEQ ID NO:129);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:130);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:131);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl), D-Ala<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO:132);
(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:133);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>37</sup>, Lys<sup>38</sup>(\mathbb{N}^{M}\underline{\mathbb{N}^{\epsilon}}-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:134);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:135);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>\epsilon</sup>-tetradecanoyl), \frac{9}{2}-Ala<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO:136);
(Aib<sup>8,37</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:137);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ado<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO:138);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ado<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:139);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-tetradecanoyl), D-Ala<sup>37</sup>)hGLP-1(7-37)OH (SEQ ID NO 140);
(Aib<sup>8,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:141);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>37</sup>, Lys<sup>38</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:142);
(Aib^{8,35}, Lys^{26}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:143);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\mathbb{N}^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:144);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:145);
(Aib<sup>8</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:146);
(Aib<sup>8</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:147);
(Aib<sup>8</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\mathbb{N}^{\epsilon}-hexadecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:148);
```

Inventor

Serial No.

Dong

10/629,261

```
Dong
Inventor
                                     10/629,261
Serial No.
                                     07/28/2003
Filed
Page
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N^{M}N^{\epsilon}-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:149);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\mathbb{N}^{\varepsilon}-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:150);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N^{M}N^{\epsilon}-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:151);
(Aib^{8,35}, Lys^{26}(N^{M}N^{\epsilon}-decanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:152);
(Aib^{8,35}, Lys^{25}, Lys^{26}(N^{M}N^{\epsilon}-octanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:153);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Lys<sup>26</sup>(N^{M}N^{\epsilon}-tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:154);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:155);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(Ν<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:156);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:157);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:158);
(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-36)NH_{2}(SEQ ID NO:159);
(Aib<sup>8</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-octanoyl), Arg<sup>34</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:160);
(Aib<sup>8</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-tetradecanoyl), Arg<sup>34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:161);
(Aib<sup>8</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\mathbb{N}^{\epsilon}-hexadecanoyl), Arg<sup>34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:162);
(Aib^8, Lys^{26}(N^M N^ε-decanoyl), Arg^{34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:163);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(\mathbb{N}^{\mathbb{N}})-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:164);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\mathbb{N}^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:165);
(Aib<sup>8,35</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>\epsilon</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:166);
(Aib^{8,35}, Arg^{26}, Lys^{34}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:167);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:168);
(Aib^{8,35}, Arg^{26}, Lys^{34}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:169);
(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:170);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:171);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:172);
(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:173);
(Aib^{8,35}, Lys^{25}, Arg^{26}, Lys^{34}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}(SEQ ID NO:174);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub>(SEQ ID NO:175);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:176);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:177);
```

(Aib<sup>8,35</sup>, Lys<sup>36</sup>( $\mathbb{N}^{\mathbb{N}}$  -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub>(SEQ ID NO:178);

Page : 12

```
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:179);
(Aib^{8,35}, Arg^{26}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:180);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:181);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:182);
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:183);
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:184);
(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-38)NH_{2}(SEQ ID NO:185);
(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:186);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:187);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:188);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-38)NH_{2} (SEQ ID NO:189);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-38)NH_{2}(SEQ ID NO:190);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-38)NH_{2} (SEQ ID NO:191);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:192);
(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:193);
(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-38)NH_{2} (SEQ ID NO:194);
(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-38)NH_{2} (SEQ ID NO:195);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-38)NH_{2} (SEQ ID NO:189);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-38)NH_{2} (SEQ ID NO:190);
(Aib^{8,35,37}, Arg2^{5,26,34}, Lys^{38}(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-38)NH_{2}(SEQ ID NO:191);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:192);
(Aib^{8,35}, Lys^{25}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:196);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:197);
(Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:198);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>\epsilon</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:199);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:200);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:201);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:202);
(Aib<sup>8</sup>, Lys<sup>34</sup>(N^{M}N^{\epsilon}-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:203);
(Aib<sup>8</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\mathbb{N}^{\epsilon}-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:204);
```

Page : 13

```
(Aib<sup>8</sup>, Lys<sup>34</sup>(\mathbb{N}^{M} N<sup>\epsilon</sup>-hexadecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:205);
(Aib<sup>8</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sub>M</sub>N<sup>ε</sup>-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:206);
(Aib<sup>8</sup>, Glu<sup>23</sup>, Lys<sup>34</sup>(N_M N^{\epsilon}-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:207);
(Aib<sup>8</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N_M N^{\epsilon}-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:208);
(Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-octanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:209);
(Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}N<sup>\epsilon</sup>-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:210);
(Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>\epsilon</sup>-hexadecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:211);
(Aib<sup>8</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\mathbb{N}^{\varepsilon}-decanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:212);
(Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:213);
(Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-tetradecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:214);
(Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\mathbb{N}^{\varepsilon}-hexadecanoyl), \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:215);
(Aib<sup>8</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>ε</sup>-decanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:216);
(Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-octanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:217);
(Aib^8, Lys^{25}, Arg^{26}, Lys^{34}(N^M N^ε-tetradecanoyl), β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:218);
(Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\mathbb{N}^{\epsilon}-hexadecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:219);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:220);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:221);
(Aib<sup>8</sup>, \beta-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>\epsilon</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:222);
(Aib^8, Arg^{26}, \beta\text{-}Ala^{35}, Lys^{36}(\underline{N^M}\underline{\underline{N^\epsilon}}\text{-}octanoyl))hGLP-1(7-36)NH_2 \text{ (SEQ ID NO:223)};
(Aib^8, Arg^{26}, β-Ala^{35}, Lys^{36}(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:224);
(Aib^8, Arg^{26}, β-Ala^{35}, Lys^{36}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:225);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:226);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(\mathbb{N}^{\mathbb{N}}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:227);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:228);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:229);
(Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:230);
(Aib<sup>8</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-tetradecanoyl), β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:231);
```

```
Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003
```

Page

NO:232);

 $(Aib^8, Lys^{25}, Arg^{26,34}, β-Ala^{35}, Lys^{36}(N^M N^E-hexadecanoyl))hGLP-1(7-36)NH_2$  (SEQ ID

(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:233);

(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\mathbb{N}^{\varepsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:234);

(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}$ -hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:235);

(Aib<sup>8</sup>, Arg<sup>25,26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\mathbb{N}^{\varepsilon}$ -decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:236);

(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl), A6c<sup>32</sup>, Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:237);

(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-tetradecanoyl), A6c<sup>32</sup>, Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:238);

(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-hexadecanoyl), A6c<sup>32</sup>, Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:239);

 $(Aib^{8,35}, A6c^{32}, Lys^{34}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:240);

(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>( $\mathbb{N}^{M}\mathbb{N}^{\varepsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:241);

(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>( $N^{M}N^{\epsilon}$ -hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:242);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:243);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:244);

 $(Aib^{8,35}, A6c^{32}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:245);

(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:246);

(Aib<sup>8,35</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:247);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:248);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:249);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:250);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Ν<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:251);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>( $N^{M}N^{\epsilon}$ -decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:252);

 $(Aib^{8,35}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:253);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:254);

(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:255);

(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:256);

(Aib<sup>8,24,35</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:257);

 $(Aib^{8,24,35}, Arg^{26}, Lys^{34}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:258);

(Aib<sup>8,24,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:259);

Page 15  $(Aib^{8,24,35}, Arg^{26}, Lys^{34}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_2$  (SEQ ID NO:260);  $(Aib^{8,24,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:261);  $(Aib^{8,24,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:262);  $(Aib^{8,24,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:263);$  $(Aib^{8,24,35}, Glu^{23}, A6c^{32}, Lys^{34}(N_MN^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:264);$  $(Aib^{8,35}, Glu^{23}, Lys^{26}(N^{M}N^{\epsilon}-octanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:265);$ (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>26</sup>( $\mathbb{N}^{M}\mathbb{N}^{\varepsilon}$ -tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:266); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>26</sup>(Ν<sup>M</sup>N<sup>ε</sup>-hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:267);  $(Aib^{8,35}, Glu^{23}, Lys^{34}(N_MN^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:268);$  $(Aib^{8,35}, Glu^{23}, A6c^{32}, Lys^{34}(N_MN^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:269);$  $(Aib^{8,35}, Glu^{23}, Arg^{26}, Lys^{34}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:270); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:271); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>( $N^{M}N^{\epsilon}$ -hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:272);  $(Aib^{8,35}, Glu^{23}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:273);$ (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:274); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\mathbb{N}^{\varepsilon}$ -hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:275);  $(Aib^{8,35}, Glu^{23}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:276);$ (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:277); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(Ν<sup>M</sup>N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:278);  $(Aib^{8,30,35}, Lys^{26}(N^{M}N^{\epsilon}-octanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:279);$ (Aib<sup>8,30,35</sup>, Lys<sup>26</sup>( $N^{M}N^{\epsilon}$ -tetradecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:280); (Aib<sup>8,30,35</sup>, Lys<sup>26</sup>( $N^{M}N^{\epsilon}$ -hexadecanoyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:281);  $(Aib^{8,30,35}, Arg^{26}, Lys^{34}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:282); (Aib<sup>8,30,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:283); (Aib<sup>8,30,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}$ -hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:284);  $(Aib^{8,30,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:285);  $(Aib^{8,30,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-tetradecanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:286);$  $(Aib^{8,30,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:287);$  $(Aib^{8,35}, Glu^{23}, A6c^{32}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:288);$ 

(Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}$ -tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:289);

```
07/28/2003
Filed
Page
                                    16
(Aib^{8,35}, Glu^{23}, A6c^{32}, Lys^{36}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:290);
(Aib^{8,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:291);
(Aib<sup>8,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Ν<sup>M</sup>Ν<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:292);
(Aib^{8,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID)
NO:293);
(Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Ν<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:294);
(Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:295);
(Aib<sup>8,24,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Ν<sup>M</sup>N<sup>ε</sup>-hexadecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:296);
(Aib^{8,24,30,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:297);
(Aib<sup>8,24,30,35</sup>, Glu<sup>23</sup>, Arg<sup>26,34</sup>, A6c<sup>32</sup>, Lys<sup>36</sup>(Ν<sup>M</sup>N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID
NO:298);
(Aib^{8,24,30,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N^{M}N^{\epsilon}-hexadecanoyl))hGLP-1(7-36)NH_{2} (SEQ ID
NO:299);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\mathbb{N}^{\varepsilon}-octanesulfonyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:317);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-dodecanesulfonyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:318);
(Aib<sup>8,35</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-hexadecanesulfonyl), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:319);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}-octanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:320);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>ε</sup>-dodecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:321);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>ε</sup>-hexadecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:322);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-octanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:323);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-hexadecanesulfonyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:324);
(Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-decylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:325);
(Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-dodecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:326);
(Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-tetradecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:327);
(Aib<sup>8,35</sup>, Asp<sup>26</sup>(1-(4-hexadecylpiperazine)), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:328);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:329);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:330);
```

Inventor

Serial No.

Dong

10/629,261

Page : 17

```
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:331);
(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Asp<sup>34</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:332);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:333);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:334);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>36</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:335);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:336);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:337);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:338);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:339);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:340);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:341);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:342);
(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:343);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Asp<sup>26</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:344);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Asp<sup>26</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:345);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Asp<sup>26</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:346);
(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Asp<sup>26</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:347);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Asp<sup>34</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:348);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Asp<sup>34</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:349);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Asp<sup>34</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:350);
(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Asp<sup>34</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:351);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>36</sup>(1-(4-decylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:352);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>36</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:353);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>36</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:354);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>36</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:355);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:356);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:357);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:358);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:359);
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-decylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:360);
```

```
Inventor : Dong
Serial No. : 10/629,261
Filed : 07/28/2003
Page : 18
```

(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:361);

(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:362);

(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Asp<sup>38</sup>(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:363);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Glu<sup>36</sup>(1-dodecylamino))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:364);

(Aib<sup>8,35</sup>, Glu<sup>26</sup>(1-dodecylamino), Arg<sup>34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:365);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Glu<sup>34</sup>(1-dodecylamino))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:366);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Glu<sup>38</sup>(1-dodecylamino))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:367);

(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:368);

(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:369);

(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:370;

(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:371);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:372);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:373);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup>ε</sup>-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:374);

(Aib<sup>8,35</sup>, Arg<sup>26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:375);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:376);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:377);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:378);

<u>Page</u>: 19

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:379);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:380);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:381);

(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>M</sup>N<sup>ε</sup>-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:382);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>M</sup>N<sup>ε</sup>-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:383);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>M</sup>N<sup>ε</sup>-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:384);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>M</sup>N<sup>ε</sup>-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:385);

(Aib<sup>8,35,37</sup>, Arg<sup>26,34</sup>, Lys<sup>38</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:386);

(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:387);

(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:388);

(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}^{\epsilon}}$ -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:389);

(Aib<sup>8,35</sup>, Arg<sup>25,34</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:390);

(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:391);

(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>( $\mathbb{N}^{M}\underline{\mathbb{N}}^{\epsilon}$ -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:392);

(Aib<sup>8,35</sup>, Arg<sup>25,26</sup>, Lys<sup>34</sup>(N<sup>M</sup>N<sup> $\epsilon$ </sup>-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:393);

```
Inventor
                             Dong
Serial No.
                              10/629,261
                              07/28/2003
Filed
Page
                              20
(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N^{M}N^{\epsilon}-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ)
ID NO:394);
(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N^{M}N^{\epsilon}-(2-(4-decyl-1-piperazine)-acetyl)))))
NO:395);
(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N^{M}N^{\epsilon}-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_{2} (SEQ
ID NO:396);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N^{M}\underline{N}^{\varepsilon}-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ
ID NO:397);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>36</sup>(N^{M}\underline{N}^{\varepsilon}-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH<sub>2</sub> (SEQ
ID NO:398);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N<sup>M</sup>N<sup>\epsilon</sup>-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ ID
NO:399);
(Aib^{8,35}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-(2-(4-dodecyl-1-piperazine)-acetyl)))))
ID NO:400);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N^{M}\underline{N}^{\varepsilon}-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ
ID NO:401);
(Aib<sup>8,35</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(\mathbb{N}^{\mathbb{N}} (2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub> (SEQ
ID NO:402);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-(2-(4-decyl-1-piperazine)-acetyl))))hGLP-1(7-38)NH_{2} (SEQ
ID NO:403);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_{2} (SEQ
ID NO:404);
(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N^{M}N^{\epsilon}-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_{2}
(SEQ ID NO:405);
(Aib<sup>8,35,37</sup>, Arg<sup>25,26,34</sup>, Lys<sup>38</sup>(N^{M}N^{\epsilon}-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH<sub>2</sub>
(SEQ ID NO:406);
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:407);
(Aib^{8,35}, Lys^{25}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:408);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ava<sup>37</sup>, Ado<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:409);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>37</sup>, Ava<sup>38</sup>, Ado<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:27);
```

```
Dong
Inventor
Serial No.
                                    10/629,261
                                    07/28/2003
Filed
Page
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Aun<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:28);
(Aib<sup>8,17,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:29);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, D-Asp<sup>37</sup>, Ava<sup>38</sup>, Aun<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:30);
(Gly<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:31);
(Ser<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:32);
(Aib<sup>8</sup>, Glu<sup>22,23</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:33);
(Gly<sup>8</sup>, Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:34);
(Aib<sup>8</sup>, Lys<sup>18</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO35);
(Aib<sup>8</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:36);
(Aib<sup>8</sup>, Lys<sup>33</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:37);
(Aib<sup>8</sup>, Lys<sup>18</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:38);
(Aib<sup>8</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:39);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:40);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:41);
(Aib<sup>8,27</sup>, β-Ala<sup>35,37</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:42);
(Aib<sup>8,27</sup>, β-Ala<sup>35,37</sup>, Arg<sup>38,39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:43);
(Aib<sup>8</sup>, Lys<sup>18,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:44);
(Aib<sup>8</sup>, Lys<sup>27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:45);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:46);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:47);
(Aib<sup>8</sup>, D-Arg<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:48);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:49);
(Aib<sup>8</sup>, Phe<sup>31</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:50);
(Aib<sup>8,35</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:51);
(Aib<sup>8,35</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:52);
(Aib<sup>8,35</sup>, Nal<sup>28,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:53);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:54);
(Aib<sup>8,35</sup>, Nal<sup>19,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:56);
```

(Aib<sup>8,35</sup>, Nal<sup>12,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:57);

(Aib<sup>8,35</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:58); (Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(N<sup>M</sup>N<sup>ε</sup>-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:59); (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-dodecanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:60); (Aib<sup>8</sup>, β-Ala<sup>35</sup>, Ser<sup>37</sup>(O-decanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:61); (Aib<sup>8,27</sup>, β-Ala<sup>35,37</sup>, Arg<sup>38</sup>, Lys<sup>39</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:62); (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:63); (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>M</sup>N<sup>ε</sup>-decanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:64); (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>M</sup>N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:65); (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>M</sup>N<sup>ε</sup>-dodecanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:410); or (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>M</sup>N<sup>ε</sup>-dodecanoyl))hGLP-1(8-37)NH<sub>2</sub> (SEQ ID NO:411); or a pharmaceutically acceptable salt thereof.

16 (currently amended): A compound according to claim 15 wherein said compound is: (Aib<sup>8,35</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:16); (Aib<sup>8,35</sup>, Glu<sup>23</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:17); (Aib 8,24,35)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:18); (Aib<sup>8,35</sup>, Glu<sup>23</sup>, A6c<sup>32</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:19); (Aib<sup>8</sup>, Glu<sup>23</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:20); (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEO ID NO:21);  $(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-octanoyl))hGLP-1(7-36)NH_{2}$  (SEQ ID NO:22);  $(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:23);$ (Aib<sup>8,35</sup>, Lys<sup>25</sup>, Arg<sup>26,34</sup>Lys<sup>36</sup>( $N^{M}N^{\epsilon}$ -decanoyl))hGLP-1(7-36)OH (SEQ ID NO:24); (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>36</sup>(N<sup>M</sup>N<sup>ε</sup>-Aec-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:25);(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Ava<sup>37</sup>, Ado<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:26); (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Asp<sup>37</sup>, Ava<sup>38</sup>, Ado<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:27); (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Aun<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:28); (Aib<sup>8,17,35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:29); (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, D-Asp<sup>37</sup>, Ava<sup>38</sup>, Aun<sup>39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:30); (Gly<sup>8</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:31);

```
23
Page
(Ser<sup>8</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:32);
(Aib<sup>8</sup>, Glu<sup>22,23</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:33);
(Gly<sup>8</sup>, Aib<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:34);
(Aib<sup>8</sup>, Lys<sup>18</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO: 35);
(Aib<sup>8</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:36);
(Aib<sup>8</sup>, Lys<sup>33</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:37);
(Aib<sup>8</sup>, Lys<sup>18</sup>, Leu<sup>27</sup>, β-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:38);
(Aib<sup>8</sup>, D-Arg<sup>36</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:39);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, D-Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:40);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:41);
(Aib^{8,27}, \beta-Ala^{35,37}, Arg^{38})hGLP-1(7-38)NH_2 (SEQ ID NO:42);
(Aib<sup>8,27</sup>, \beta-Ala<sup>35,37</sup>, Arg<sup>38,39</sup>)hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:43);
(Aib<sup>8</sup>, Lys<sup>18,27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:44);
(Aib<sup>8</sup>, Lys<sup>27</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:45);
(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Arg<sup>38</sup>)hGLP-1(7-38)NH<sub>2</sub> (SEQ ID NO:46);
(Aib<sup>8</sup>, Arg<sup>26,34</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:47);
(Aib<sup>8</sup>, D-Arg<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:48);
(Aib<sup>8</sup>, \beta-Ala<sup>35</sup>, Arg<sup>37</sup>)hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:49);
(Aib<sup>8</sup>, Phe<sup>31</sup>, \beta-Ala<sup>35</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:50);
(Aib<sup>8,35</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:51);
(Aib<sup>8,35</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:52);
(Aib<sup>8,35</sup>, Nal<sup>28,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:53);
(Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Nal<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:54);
(Aib<sup>8,35</sup>, Nal<sup>19,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:56);
(Aib<sup>8,35</sup>, Nal<sup>12,31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:57);
(Aib<sup>8,35</sup>, Lys<sup>36</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:58);
(Aib<sup>8,35</sup>, Arg<sup>34</sup>, Lys<sup>26</sup>(\mathbb{N}^{M}\underline{\mathbb{N}}^{\varepsilon}-decanoyl))hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:59);
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N^{M}N^{\epsilon}-dodecanoyl))hGLP-1(7-36)NH_{2} (SEQ ID NO:60);
```

(Aib<sup>8</sup>, β-Ala<sup>35</sup>, Ser<sup>37</sup>(O-decanoyl))hGLP-1(7-37)-NH<sub>2</sub> (SEQ ID NO:61);

(Aib<sup>8,27</sup>, β-Ala<sup>35,37</sup>, Arg<sup>38</sup>, Lys<sup>39</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-39)NH<sub>2</sub> (SEQ ID NO:62); (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>M</sup>N<sup>ε</sup>-octanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:63); (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>M</sup>N<sup>ε</sup>-decanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:64); or (Aib<sup>8</sup>, Arg<sup>26,34</sup>, β-Ala<sup>35</sup>, Lys<sup>37</sup>(N<sup>M</sup>N<sup>ε</sup>-tetradecanoyl))hGLP-1(7-37)NH<sub>2</sub> (SEQ ID NO:65); or a pharmaceutically acceptable salt thereof.

17-18 (canceled)

19 (previously presented): A compound wherein said compound is: (Aib<sup>8,35</sup>, Arg<sup>26,34</sup>, Phe<sup>31</sup>)hGLP-1(7-36)NH<sub>2</sub> (SEQ ID NO:55); or a pharmaceutically acceptable salt thereof.